MIT engineers design more powerful RNA vaccines
The new approach could lead to intranasal vaccines for Covid-19 and other respiratory diseases.
The new approach could lead to intranasal vaccines for Covid-19 and other respiratory diseases.
The Koch Institute’s Annual Symposium highlights emerging successes and challenges in the advancement of vaccines to prevent and treat cancer.
A pilot-scale system, enabled by an $82 million award from the FDA, aims to accelerate the development and production of mRNA technologies.
The new strategy may enable engineered T cells to eradicate solid tumors such as glioblastoma.
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice.
The illustrious prize supports early-career scientists and engineers as they pursue interdisciplinary work.
The method could enable a rapid test to determine whether individuals are producing antibodies that help protect against Covid-19.
The printer generates vaccine-filled microneedle patches that can be stored long-term at room temperature and applied to the skin.
A survey to measure who was getting vaccinated against Covid-19 in Uganda finds health workers had an important role to play.
The global health care company Sanofi is providing $25 million to advance RNA research.
Aided by machine learning, scientists are working to develop a vaccine that would be effective against all SARS-CoV-2 strains.
MIT engineers find specialized nanoparticles can quickly and inexpensively isolate proteins from a bioreactor.
New fellows are working on health records, robot control, pandemic preparedness, brain injuries, and more.
At an exhibition marking two decades since a transformative gift from the Picower Foundation, current and alumni members described research at the forefront of neuroscience and beyond.
Test that measures a person’s antibodies requires a drop of blood and takes just 10 minutes to show results.